The researchers examined 52 patients randomized into two cohorts either receiving Actifuse combined with 5 mL of bone marrow aspirate or 4.2 mg of rhBMP-2. The researchers found that one year after surgery 65 percent of the Actifuse cohort and 92 percent of the rhBMP-2 cohort showed radiographical arthrodesis.
The patients also reported improvement in visual analogue scale scores in both groups. Pseudoarthrosis rates were 35 percent for Actifuse and 7.7 percent for rhBMP-2 at one year postoperatively. The researchers also noted higher reoperation rates among the Actifuse patients.
The researchers concluded, “Additional analysis of Actifuse and other graft enhancers/extenders are needed prior to the utilization for an MIS TLIF.”
More Articles on Spine Surgery:
Benefits, Economics & Process of Outpatient Spine Surgery in ASCs: Q&A With Dr. William Tally
Minimally Invasive Spine Surgery: 4 Quality of Life Findings for TLIF
5 Biggest Payment Problems in Spine & Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.